Ra Medical Systems Inc. Receives Continued Listing Standard Notice from the NYSE

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced receipt of written notice from The New York Stock Exchange (the “NYSE”) indicating that Ra Medical is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.

In accordance with Section 802.01C of the NYSE’s Listed Company Manual, Ra Medical has a period of six months, to regain compliance with the average closing share price requirement. In response to the COVID-19 pandemic, the NYSE is tolling compliance periods until at least June 30, 2020. If such tolling period is not further extended, Ra Medical must regain compliance by December 31, 2020. To regain compliance, on the last trading day of any calendar month during the cure period, Ra Medical’s common stock must have (i) a closing price of at least $1.00 per share and (ii) an average closing price of at least $1.00 per share over the 30-trading day period ending on the last trading day of such month. If Ra Medical is unable to regain compliance, the NYSE will initiate procedures to suspend and delist Ra Medical’s common stock.

The notification has no immediate effect on the listing of Ra Medical’s common stock, which will continue to be listed and traded on the NYSE during the cure period, subject to Ra Medical’s compliance with the other listing requirements of the NYSE. Ra Medical’s common stock will continue to trade under the symbol “RMED” but will have an added designation of “.BC” to indicate the status of the common stock as “below compliance” with the NYSE’s continued listing standards. The “.BC” indicator will be removed at such time as Ra Medical regains compliance.

Ra Medical intends to monitor the closing price of its common stock and consider implementing available options to regain compliance with the average closing share price requirement.



Subscribe to Medical Device News Magazine

Related Articles